Advaxis announced that the FDA has granted ADXS-HPV Orphan Drug Designation for the treatment of human papillomavirus (HPV)-associated head and neck cancer.
Related: Head and Neck Cancer Resource Center
ADXS-HPV is an immunotherapy designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy.
Previously the FDA granted ADXS-HPV Orphan Drug Designation for the treatment of human papillomavirus (HPV)-associated anal cancer.
ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer, locally advanced cervical cancer, head & neck cancer, and anal cancer.
For more information call (609) 452-9813 or visit Advaxis.com.
This article originally appeared on MPR